^
Association details:
| Biomarker: | MLL rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | mivavotinib (CB-659) (FLT3 inhibitor, SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3039 - Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia
Published date:
03/10/2021
Excerpt:
...8 B-lineage pediatric ALL PDXs...4 mixed-lineage leukemia-rearranged, MLLr...The in vivo efficacy of TAK-659 was evaluated...Only one MLLr-ALL obtained an objective response (partial response) with all other models exhibiting progressive disease.
